| P50 | author | Haya Ascher-Svanum | Q72984589 |
| P2093 | author name string | Baojin Zhu | |
| | Marvin Swartz | |
| | Douglas Faries | |
| | Jeff Swanson | |
| | Ron Landbloom | |
| P2860 | cites work | Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis | Q24645193 |
| | A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia | Q24794849 |
| | Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics | Q24811190 |
| | Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs | Q25257471 |
| | Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 |
| | Using drug claims data to assess the relationship of medication adherence with hospitalization and costs | Q30652843 |
| | Dropout rates in randomised antipsychotic drug trials | Q30684652 |
| | Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission | Q30714937 |
| | Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine | Q31864356 |
| | Effect of mental health specialty care on antidepressant length of therapy | Q33601811 |
| | Episodes of mental health and substance abuse treatment under a managed behavioral health care carve-out. | Q33718657 |
| | Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy | Q33897832 |
| | Practice guideline for the treatment of patients with schizophrenia, second edition. | Q33976372 |
| | New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis | Q34196968 |
| | Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials | Q34205157 |
| | A meta-analysis of the efficacy of second-generation antipsychotics | Q34534321 |
| | Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature | Q34989186 |
| | An economic review of compliance with medication therapy in the treatment of schizophrenia | Q35094083 |
| | Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. | Q35165445 |
| | Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia | Q35855167 |
| | Compliance with medication regimens for mental and physical disorders | Q38552093 |
| | Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group | Q39605645 |
| | Estimation of antipsychotic effects on hospitalization risk in a naturalistic study with selection on unobservables | Q40532436 |
| | Predictors of Risk of Nonadherence in Outpatients With Schizophrenia and Other Psychotic Disorders | Q44402066 |
| | Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients | Q44492664 |
| | The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): an instrument to assess outcomes of schizophrenia care | Q44613827 |
| | Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial | Q44674061 |
| | Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia | Q44701045 |
| | The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population | Q44726455 |
| | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol | Q44850771 |
| | Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment | Q44920431 |
| | Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator | Q45214860 |
| | Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial | Q46494999 |
| | Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. | Q46639910 |
| | Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia | Q47314881 |
| | Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative | Q48102710 |
| | Less medication switching after initial start with atypical antipsychotics. | Q51945024 |
| | Atypical Antipsychotics in First Admission Schizophrenia: Medication Continuation and Outcomes | Q51945801 |
| | A sharper Bonferroni procedure for multiple tests of significance | Q56622251 |
| | Intermittent vs maintenance medication in schizophrenia. Two-year results | Q68294950 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 8 | |
| P577 | publication date | 2006-02-21 | |
| P1433 | published in | BMC Psychiatry | Q15750257 |
| P1476 | title | Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia | |
| P478 | volume | 6 | |